Please note that the details of this Challenge are no longer open. This challenge is awarded and is no longer accepting new submissions. You can:
Challenge Potential Drug Targets for Kinetoplastid Infectious Diseases
Potential Drug Targets for Kinetoplastid Infectious Diseases
STATUS: Awarded
Active Solvers: 314
Posted: Jan 28 2010
Challenge ID: 9145905
Share Challenge Share
The Drugs for Neglected Diseases initiative (DNDi), is looking for potential drug targets for kinetoplastid infectious diseases affecting the developing world (African Sleeping Sickness, Visceral Leishmaniasis, Cutaneous Leishmaniasis, and Chagas Disease). The focus is on chemically validated targets and associated small molecules.

This Challenge requires only a written proposal.
The Seeker for this Challenge, The Drugs for Neglected Diseases initiative (DNDi, a Geneva based not-for-profit Product Development Partnership chartered with development of new treatments for so-called neglected diseases) is looking for potential targets for anti-kinetoplastid drugs and small molecule compounds that could be used to validate these targets. DNDi is not seeking access to currently available databases for drug targets but specifically a list of potential drug targets together with a list of small molecule inhibitors supported by evidence of the specificity of the inhibitors.

The Challenge requires only a written proposal, and the Solvers are not required to transfer exclusive intellectual property rights to it to the Seeker. Rather, the Solvers will grant the Seeker a royalty-free, non-exclusive license to practice their proposals.

This Challenge is sponsored by Nature Publishing Group.
What is InnoCentive?
InnoCentive is the global innovation marketplace where creative minds solve some of the world's most important problems for cash awards up to $1 million. Commercial, governmental and humanitarian organizations engage with InnoCentive to solve problems that can impact humankind in areas ranging from the environment to medical advancements.

What is a Theoretical-Licensing Challenge?

An InnoCentive Theoretical Challenge builds upon an idea but is not yet a proof of concept. A solution to a Theoretical Challenge will solidify the Solver's concept with detailed descriptions, specifications and requirements necessary to bringing a good idea closer to becoming an actual product or service.

This Challenge is a Theoretical-Licensing Challenge, meaning that the Seeker is requesting non-exclusive rights to use the winning solution. By contrast, Theoretical-IP Transfer means that Solvers must relinquish all rights to the Intellectual Property (IP) for which they are awarded. For these forms of a Theoretical Challenge, Solvers that do not win retain the rights to their solution after the evaluation period is complete. The Seeker retains no rights to any IP not awarded.

Share This Challenge
InnoCentive Trust Partners